345 related articles for article (PubMed ID: 26763083)
1. Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer.
Schmid M; Hanske J; Ravi P; Krishna N; Reznor G; Meyer CP; Fisch M; Noldus J; Nguyen PL; Trinh QD
Int J Urol; 2016 Apr; 23(4):305-11. PubMed ID: 26763083
[TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation therapy for prostate cancer and the risk of hospitalisation for community-acquired pneumonia.
Hicks BM; Yin H; Bladou F; Ernst P; Azoulay L
Thorax; 2017 Jul; 72(7):596-597. PubMed ID: 27986803
[TBL] [Abstract][Full Text] [Related]
3. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
Keating NL; O'Malley AJ; Smith MR
J Clin Oncol; 2006 Sep; 24(27):4448-56. PubMed ID: 16983113
[TBL] [Abstract][Full Text] [Related]
4. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
[TBL] [Abstract][Full Text] [Related]
5. Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer.
Sammon JD; Abdollah F; Reznor G; Pucheril D; Choueiri TK; Hu JC; Kim SP; Schmid M; Sood A; Sun M; Kibel AS; Nguyen PL; Menon M; Trinh QD
Eur Urol; 2015 Jul; 68(1):32-9. PubMed ID: 25457017
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.
Sun M; Choueiri TK; Hamnvik OP; Preston MA; De Velasco G; Jiang W; Loeb S; Nguyen PL; Trinh QD
JAMA Oncol; 2016 Apr; 2(4):500-7. PubMed ID: 26720632
[TBL] [Abstract][Full Text] [Related]
7. Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events.
Schmid M; Sammon JD; Reznor G; Kapoor V; Speed JM; Abdollah FA; Sood A; Chun FK; Kibel AS; Menon M; Fisch M; Sun M; Trinh QD
BJU Int; 2016 Aug; 118(2):221-9. PubMed ID: 26074405
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.
Wu CT; Yang YH; Chen PC; Chen MF; Chen WC
Osteoporos Int; 2015 Sep; 26(9):2281-90. PubMed ID: 25990353
[TBL] [Abstract][Full Text] [Related]
9. Risk of fracture after androgen deprivation for prostate cancer.
Shahinian VB; Kuo YF; Freeman JL; Goodwin JS
N Engl J Med; 2005 Jan; 352(2):154-64. PubMed ID: 15647578
[TBL] [Abstract][Full Text] [Related]
10. Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer.
Gillessen S; Templeton A; Marra G; Kuo YF; Valtorta E; Shahinian VB
J Natl Cancer Inst; 2010 Dec; 102(23):1760-70. PubMed ID: 21068432
[TBL] [Abstract][Full Text] [Related]
11. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
12. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.
Crawley D; Garmo H; Rudman S; Stattin P; Häggström C; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M
Int J Cancer; 2016 Dec; 139(12):2698-2704. PubMed ID: 27557616
[TBL] [Abstract][Full Text] [Related]
13. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
Keating NL; O'Malley AJ; Freedland SJ; Smith MR
J Natl Cancer Inst; 2010 Jan; 102(1):39-46. PubMed ID: 19996060
[TBL] [Abstract][Full Text] [Related]
14. Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study.
Tsai HT; Pfeiffer RM; Philips GK; Barac A; Fu AZ; Penson DF; Zhou Y; Potosky AL
J Urol; 2017 May; 197(5):1251-1257. PubMed ID: 27993663
[TBL] [Abstract][Full Text] [Related]
15. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.
Klil-Drori AJ; Yin H; Tagalakis V; Aprikian A; Azoulay L
Eur Urol; 2016 Jul; 70(1):56-61. PubMed ID: 26138040
[TBL] [Abstract][Full Text] [Related]
16. Androgen Deprivation Therapy and the Risk of Anemia in Men with Prostate Cancer.
Hicks BM; Klil-Drori AJ; Yin H; Campeau L; Azoulay L
Epidemiology; 2017 Sep; 28(5):712-718. PubMed ID: 28768300
[TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
Saigal CS; Gore JL; Krupski TL; Hanley J; Schonlau M; Litwin MS;
Cancer; 2007 Oct; 110(7):1493-500. PubMed ID: 17657815
[TBL] [Abstract][Full Text] [Related]
19. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
20. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
O'Farrell S; Garmo H; Holmberg L; Adolfsson J; Stattin P; Van Hemelrijck M
J Clin Oncol; 2015 Apr; 33(11):1243-51. PubMed ID: 25732167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
